Wednesday, September 24, 2014 5:35:09 AM
"The NDA for Macrilen™ continues to be under review, with a PDUFA date of November 5".
• Continued discussions with the FDA and provided the agency with further information regarding the New Drug Application ("NDA") review for Macrilen™, which seeks approval as the first orally-administered drug for the evaluation of Adult Growth Hormone Deficiency ("AGHD"). Prescription Drug User Fee Act ("PDUFA") date set for November 5, 2014.
• Dennis Turpin, CFO of Aeterna Zentaris commented, "With our cash position, combined with the streamlining of our R&D activities, we are able to continue to advance our strategic programs and reach our near-term milestones related to Macrilen™ and zoptarelin doxorubicin."
Unless I'm missing someting.
http://www.sec.gov/Archives/edgar/data/1113423/000111342314000019/exhibit991pr-q2x2014.htm
Kei said:
Saturday, September 20, 2014 11:22:58 AM
AEZS - only 32 trading days to PDUFA! this is in my view only, but, AEZS will get a lot of attention after september (after PGNX & PSDV this month) since not much is going on in the bio-land at all in octoberrrr...hence, i don't think the pps will go down to $1.25 area as you said.
NAVB October 17th
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent AEZS News
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
